The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained
Authors
Keywords
Histology, NAFLD, Outcomes, Pathology
Journal
Clinical Gastroenterology and Hepatology
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-06-05
DOI
10.1016/j.cgh.2021.05.059
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment candidacy for pharmacologic therapies for NASH
- (2021) Ian A. Rowe et al. Clinical Gastroenterology and Hepatology
- A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
- (2021) Amaro Taylor‐Weiner et al. HEPATOLOGY
- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
- (2020) Rod S. Taylor et al. GASTROENTEROLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
- (2020) Beth A. Davison et al. JOURNAL OF HEPATOLOGY
- Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
- (2020) Anna Roskilly et al. LIVER INTERNATIONAL
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
- (2019) Arun J. Sanyal et al. HEPATOLOGY
- Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
- (2019) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH
- (2019) Rohit Loomba et al. HEPATOLOGY
- qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis
- (2019) Feng Liu et al. HEPATOLOGY
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease
- (2018) Andrew J. Muir et al. HEPATOLOGY
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- The devotion to surrogate outcomes in drug development for liver disease
- (2017) Ian A. Rowe Nature Reviews Gastroenterology & Hepatology
- Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
- (2015) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Effects of Liver Biopsy Sample Length and Number of Readings on Sampling Variability in Nonalcoholic Fatty Liver Disease
- (2008) Raj Vuppalanchi et al. Clinical Gastroenterology and Hepatology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search